Takeda Pharmaceutical Company
Takeda Pharmaceutical Co., Ltd. (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.
Global headquarters in Nihonbashi
|Takeda Yakuhin Kōgyō kabushiki gaisha|
|Takeda Chemical Industries, Ltd. (English name only until June 31, 2004)|
|Founded||Doshomachi, Osaka, Japan (June 12, 1781 )|
|Founder||Choubee Takeda |
(Chairman of the Board)
(President & CEO)
|Owner||Nippon Life (6.79%)|
Number of employees
|Website||takeda.com (Global website)|
|Footnotes / references|
Takeda Pharmaceuticals was founded on June 12, 1781, and was incorporated on January 29, 1925.
In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals. Through TAP Pharmaceuticals, Takeda and Abbott launched the blockbusters Lupron (leuprorelin) in 1985 and Prevacid (lansoprazole) in 1995.
One of the firm's mainstay drugs is Actos (pioglitazone), a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. Launched in 1999, Actos became the best-selling diabetes drug in the world with US$4 billion in sales during the 2008 fiscal year.
In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market. In March 2008, Takeda and Abbott Laboratories announced plans to conclude their 30-year-old joint venture, TAP Pharmaceuticals, that had over US$3 billion in sales in its final year. The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff. On the other hand, Takeda received rights to Prevacid and TAP's pipeline candidates. The move also increased Takeda's headcount by 3,000 employees. In April 2008, Takeda announced that it was acquiring Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for US$8.8 billion. The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary, "Millennium: The Takeda Oncology Company." In May 2008, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.
On April 11, 2012, Takeda Pharmaceutical and URL Pharma announced that Takeda would acquire URL Pharma, then run by the founder's son Richard Roberts, for US$800 million. The acquisition was completed by June 4, 2012. On 25 May 2012, Takeda announced the purchase of Brazilian pharmaceutical company Multilab by R$540 million.
On 26 September 2014, Takeda announced it would team up with BioMotiv with the stated aim of identifying and developing new compounds over a five-year period, worth approximately US$25 million. On 30 September 2014, Takeda announced its intention to expand a collaboration with MacroGenics, valued up to US$1.6 billion. The collaboration will focus on the co-development of the preclinical autoimmune compound MGD010. MGD010 is a therapy which targets the B-cell surface proteins CD32B and CD79B, and is indicated for lupus and rheumatoid arthritis.
In 2015, Takeda sold its respiratory drugs business to the Swedish-British AstraZeneca for $575 million (about £383 million), a deal that included roflumilast and ciclesonide. On November 20, 2015, the U.S. Food and Drug Administration approved Ixazomib developed by Takeda for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy.
In January 2017, Takeda announced it would acquire Ariad Pharmaceuticals for $5.2 billion, expanding the company's oncology and hematology divisions. The acquisition of Ariad closed on February 16, 2017.
In early January 2018, the company announced it would acquire stem cell therapy developer, TiGenix, for up to €520 million ($632 million).
In January 2019, Takeda completed acquisition of Shire for more than US$50 billion.
In October 2019, Takeda announced it will sell a portfolio of over-the-counter and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino International for more than $200 million.
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
|Takeda Pharmaceutical Company|
Takeda operates two primary bases in Japan in Osaka and Tokyo. Its United States subsidiary is based in Cambridge, Massachusetts, and all Global Operations outside Japan and U.S. are based in Opfikon (Zurich), Switzerland. The company maintains research and development sites in Japan, the United States, the United Kingdom and Singapore, with manufacturing facilities across the globe.
In April 2015 Takeda agreed to pay a settlement of $2.37 billion to an estimated 9,000 people who submitted claims alleging that pioglitazone was responsible for giving them bladder cancer. In 2014, a plaintiff was awarded $9 billion in punitive damages after a federal court found Takeda hid the cancer risks of their diabetes medicine, but the amount was later reduced to $26 million by a judge who deemed the charge excessive.
- "Takeda Pharmaceutical Company - Profile". Zoominfo.com. Retrieved 2 October 2019.
- Chris Gallagher (2015-03-15). Muralikumar Anantharaman (ed.). "Japan drugmaker Takeda says Christophe Weber to become CEO April 1". Reuters. Retrieved 2015-04-20.
- "Financial Results for Fiscal 2012" (PDF). Takeda Pharmaceutical Company Limited. 2013-05-09. Retrieved 2013-06-13.
- "Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes". Newsblaze.com. 2009-08-28. Archived from the original on 2012-05-04. Retrieved 2010-09-18.
- "FAQ." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Q : Where is Takeda located? A : The Head Office is located in Osaka, Japan, and the Tokyo Head Office is located in Tokyo, Japan."
- "Overview." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Headquarters Head Office 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645" and "Tokyo Head Office 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668"
- "100 Best Companies to Work For 2012". Fortune. 2012-02-06. Retrieved 2018-03-29.
- "TAP Pharmaceutical Products, Inc.: Private Company Information - BusinessWeek". Investing.businessweek.com. 2008-04-30. Retrieved 2010-09-18.
- Decker, Susan (2009-07-06). "Takeda Sues Torrent to Stop Generic Copy of Actos Diabetes Pill". Bloomberg. Retrieved 2010-09-18.
- Somers, Terri (2005-02-08). "Japanese drug giant taking over Syrrx here | The San Diego Union-Tribune". Signonsandiego.com. Retrieved 2010-09-18.
- "Takeda, Amgen in exclusive tie-up for Japanese market". MarketWatch. 2008-02-04. Retrieved 2010-09-18.
- Marrazzo, Amanda (2008-05-15). "Featured Articles From The Chicago Tribune". Archives.chicagotribune.com. Retrieved 2010-09-18.
- "MILLENNIUM: The Takeda Oncology Company | About Millennium | Our History". Mlnm.com. Retrieved 2010-09-18.
- staff (2008-06-15). "Takeda Signs On as Alnylam's Asian Partner for $150M Upfront". Genetic Engineering & Biotechnology News (print). Mary Ann Liebert, Inc. p. 14.
- Limited, Takeda Pharmaceutical Company. "Takeda completes acquisition and names new CEO of Nycomed - Takeda Pharmaceutical Company Limited".
- Limited, Takeda Pharmaceutical Company. "Takeda Completes Acquisition of URL Pharma, Inc. - Takeda Pharmaceutical Company Limited".
- Hirschler, Ben (2012-05-25). "Farmacêutica Takeda comprará Multilab por até R$ 540 mi". Grupo Abril (in Portuguese). Exame. Retrieved 2013-01-27.
- "Takeda, BioMotiv Launch $25M Drug Development Partnership". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. 2014-09-26. Retrieved 2015-04-23.
- "Takeda, MacroGenics Launch Up to $1.6B Expansion of DART Collaboration". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. 2014-09-30. Retrieved 2015-04-23.
- Julia Bradshaw for The Daily Telegraph, 16 December 2015. AstraZeneca to buy Takeda's lung business for £383m.Accessed: 17 December 2015.
- "Press Announcements — FDA approves Ninlaro, new oral medication to treat multiple myeloma". U.S. Food and Drug Administration. Retrieved 24 April 2016.
- "Takeda Spins Out Research Team into Neuroscience Startup". 2016-12-02.
- "Takeda to Acquire ARIAD Pharmaceuticals for $5.2B". 2017-01-09.
- "Takeda to Acquire TiGenix for €520M". 2018-01-05.
- Du, Lisa; Takahashi, Maiko (8 May 2018). "Takeda Clinches $62 Billion Deal to Buy Drugmaker Shire". Bloomberg. Retrieved 6 July 2019.
- Philippidis, Alex (1 July 2019). "Top 10 M&A Deasl of January—June 2019". Genetic Engineering & Biotechnology News.
And it didn’t include earlier-announced deals completed in 2019, such as Takeda Pharmaceutical’s £46 billion ($58.6 billion) purchase of Shire.
- "Takeda sells Mideast, Africa drug portfolio to Switzerland's Acino". Reuters. 2019-10-15. Retrieved 2019-10-15.
- "Takeda wraps 30 emerging markets drugs in $200M selloff to Swiss pharma Acino". FiercePharma. Retrieved 2019-10-15.
- "Takeda Agrees to Pay $2.4 Billion to Settle Suits Over Cancer Risk of Actos". The New York Times. 29 April 2015.
- Feeley, Jef; Matsuyama, Kanoko (9 April 2014). "Takeda, Lilly Jury Awards $9 Billion Over Actos Risks" – via www.bloomberg.com.
- "Japan's Takeda Agrees To $2.4B Settlement In Diabetes Drug Actos Lawsuit Over Cancer Risk Allegations". 29 April 2015.